2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy

Fausto Roila, David Warr, Paul J Hesketh, Richard Gralla, Jorn Herrstedt, Karin Jordan, Matti Aapro, Enzo Ballatori, Bernardo Rapoport

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

PURPOSE: An update of the recommendations for the prophylaxis of acute and delayed emesis induced by moderately emetogenic chemotherapy published after the last MASCC/ESMO antiemetic consensus conference in 2009 has been carried out.

METHODS: A systematic literature search using PubMed from January 1, 2009 to January 6, 2015 with a restriction to papers in English was conducted.

RESULTS: Overall, two randomized phase II and seven randomized phase III studies plus the results of three subgroup analysis of large phase III trials and those of a pilot study have been included.

CONCLUSIONS: In carboplatin-treated patients, a moderate benefit from adding an NK1 receptor antagonist to dexamethasone and a 5-HT3 receptor antagonist has been shown. However, in oxaliplatin-treated patients, contrasting results about the role of NK1 receptor antagonists have been obtained. At present, it is not possible to suggest a specific 5-HT3 receptor antagonist to use for the prevention of acute emesis in these patients. No routine prophylaxis for delayed emesis is recommended but in patients receiving moderately emetogenic chemotherapy with known potential for delayed emesis (e.g., oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2-3 can be considered.

OriginalsprogEngelsk
TidsskriftSupportive Care in Cancer
Vol/bind25
Udgave nummer1
Sider (fra-til)289-294
ISSN0941-4355
DOI
StatusUdgivet - 2017

Fingeraftryk

oxaliplatin
Carboplatin
PubMed

Citer dette

Roila, Fausto ; Warr, David ; Hesketh, Paul J ; Gralla, Richard ; Herrstedt, Jorn ; Jordan, Karin ; Aapro, Matti ; Ballatori, Enzo ; Rapoport, Bernardo. / 2016 updated MASCC/ESMO consensus recommendations : Prevention of nausea and vomiting following moderately emetogenic chemotherapy. I: Supportive Care in Cancer. 2017 ; Bind 25, Nr. 1. s. 289-294.
@article{333610792b0241d4aff7e1ed831f499c,
title = "2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy",
abstract = "PURPOSE: An update of the recommendations for the prophylaxis of acute and delayed emesis induced by moderately emetogenic chemotherapy published after the last MASCC/ESMO antiemetic consensus conference in 2009 has been carried out.METHODS: A systematic literature search using PubMed from January 1, 2009 to January 6, 2015 with a restriction to papers in English was conducted.RESULTS: Overall, two randomized phase II and seven randomized phase III studies plus the results of three subgroup analysis of large phase III trials and those of a pilot study have been included.CONCLUSIONS: In carboplatin-treated patients, a moderate benefit from adding an NK1 receptor antagonist to dexamethasone and a 5-HT3 receptor antagonist has been shown. However, in oxaliplatin-treated patients, contrasting results about the role of NK1 receptor antagonists have been obtained. At present, it is not possible to suggest a specific 5-HT3 receptor antagonist to use for the prevention of acute emesis in these patients. No routine prophylaxis for delayed emesis is recommended but in patients receiving moderately emetogenic chemotherapy with known potential for delayed emesis (e.g., oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2-3 can be considered.",
author = "Fausto Roila and David Warr and Hesketh, {Paul J} and Richard Gralla and Jorn Herrstedt and Karin Jordan and Matti Aapro and Enzo Ballatori and Bernardo Rapoport",
year = "2017",
doi = "10.1007/s00520-016-3365-1",
language = "English",
volume = "25",
pages = "289--294",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Heinemann",
number = "1",

}

Roila, F, Warr, D, Hesketh, PJ, Gralla, R, Herrstedt, J, Jordan, K, Aapro, M, Ballatori, E & Rapoport, B 2017, '2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy', Supportive Care in Cancer, bind 25, nr. 1, s. 289-294. https://doi.org/10.1007/s00520-016-3365-1

2016 updated MASCC/ESMO consensus recommendations : Prevention of nausea and vomiting following moderately emetogenic chemotherapy. / Roila, Fausto; Warr, David; Hesketh, Paul J; Gralla, Richard; Herrstedt, Jorn; Jordan, Karin; Aapro, Matti; Ballatori, Enzo; Rapoport, Bernardo.

I: Supportive Care in Cancer, Bind 25, Nr. 1, 2017, s. 289-294.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - 2016 updated MASCC/ESMO consensus recommendations

T2 - Prevention of nausea and vomiting following moderately emetogenic chemotherapy

AU - Roila, Fausto

AU - Warr, David

AU - Hesketh, Paul J

AU - Gralla, Richard

AU - Herrstedt, Jorn

AU - Jordan, Karin

AU - Aapro, Matti

AU - Ballatori, Enzo

AU - Rapoport, Bernardo

PY - 2017

Y1 - 2017

N2 - PURPOSE: An update of the recommendations for the prophylaxis of acute and delayed emesis induced by moderately emetogenic chemotherapy published after the last MASCC/ESMO antiemetic consensus conference in 2009 has been carried out.METHODS: A systematic literature search using PubMed from January 1, 2009 to January 6, 2015 with a restriction to papers in English was conducted.RESULTS: Overall, two randomized phase II and seven randomized phase III studies plus the results of three subgroup analysis of large phase III trials and those of a pilot study have been included.CONCLUSIONS: In carboplatin-treated patients, a moderate benefit from adding an NK1 receptor antagonist to dexamethasone and a 5-HT3 receptor antagonist has been shown. However, in oxaliplatin-treated patients, contrasting results about the role of NK1 receptor antagonists have been obtained. At present, it is not possible to suggest a specific 5-HT3 receptor antagonist to use for the prevention of acute emesis in these patients. No routine prophylaxis for delayed emesis is recommended but in patients receiving moderately emetogenic chemotherapy with known potential for delayed emesis (e.g., oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2-3 can be considered.

AB - PURPOSE: An update of the recommendations for the prophylaxis of acute and delayed emesis induced by moderately emetogenic chemotherapy published after the last MASCC/ESMO antiemetic consensus conference in 2009 has been carried out.METHODS: A systematic literature search using PubMed from January 1, 2009 to January 6, 2015 with a restriction to papers in English was conducted.RESULTS: Overall, two randomized phase II and seven randomized phase III studies plus the results of three subgroup analysis of large phase III trials and those of a pilot study have been included.CONCLUSIONS: In carboplatin-treated patients, a moderate benefit from adding an NK1 receptor antagonist to dexamethasone and a 5-HT3 receptor antagonist has been shown. However, in oxaliplatin-treated patients, contrasting results about the role of NK1 receptor antagonists have been obtained. At present, it is not possible to suggest a specific 5-HT3 receptor antagonist to use for the prevention of acute emesis in these patients. No routine prophylaxis for delayed emesis is recommended but in patients receiving moderately emetogenic chemotherapy with known potential for delayed emesis (e.g., oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2-3 can be considered.

U2 - 10.1007/s00520-016-3365-1

DO - 10.1007/s00520-016-3365-1

M3 - Journal article

C2 - 27510316

VL - 25

SP - 289

EP - 294

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 1

ER -